Who are incobotulinumtoxinA (Xeomin)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Botox, Botulinum Toxin-A injection, Chemodenervation (4 months), Dysport® (abobotulinumtoxinA), Onabotulinumtoxin A (BoNT), Botulinum Toxin Type A 900kD.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/incobotulinumtoxina-xeomin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

incobotulinumtoxinA (Xeomin) — Competitive Intelligence Brief

incobotulinumtoxinA (Xeomin) (incobotulinumtoxinA (Xeomin)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: botulinum toxin. Area: Neurology.

phase 3 botulinum toxin SNAP-25 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

incobotulinumtoxinA (Xeomin) (incobotulinumtoxinA (Xeomin)) — Merz Pharmaceuticals GmbH. IncobotulinumtoxinA is a botulinum toxin type A that works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contractions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
incobotulinumtoxinA (Xeomin) TARGET	incobotulinumtoxinA (Xeomin)	Merz Pharmaceuticals GmbH	phase 3	botulinum toxin	SNAP-25
Botox	ONABOTULINUMTOXINA	Allergan	marketed	Acetylcholine Release Inhibitor [EPC]	SNAP-25	2010-01-01
Botulinum Toxin-A injection	Botulinum Toxin-A injection	Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust	marketed	Neurotoxin; neuromuscular blocking agent	SNARE complex (specifically cleaves SNAP-25)
Chemodenervation (4 months)	Chemodenervation (4 months)	University of Wisconsin, Madison	marketed	Botulinum toxin	SNARE complex (synaptobrevin, SNAP-25, syntaxin)
Dysport® (abobotulinumtoxinA)	Dysport® (abobotulinumtoxinA)	Seoul National University Hospital	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Onabotulinumtoxin A (BoNT)	Onabotulinumtoxin A (BoNT)	Edgar LeClaire, MD	marketed	Neurotoxin; botulinum toxin serotype A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin Type A 900kD	Botulinum Toxin Type A 900kD	Allergan	marketed	Neurotoxin; acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (botulinum toxin class)

Merz Pharmaceuticals GmbH · 2 drugs in this class
Allergan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). incobotulinumtoxinA (Xeomin) — Competitive Intelligence Brief. https://druglandscape.com/ci/incobotulinumtoxina-xeomin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab